Triochem Products
17.40
0.00(0.00%)
Market Cap₹0.40 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D0.00%
1M0.00%
6M0.00%
1Y0.00%
5Y0.00%
View Company Insightsright
More news about Triochem Products
19Mar 26
Triochem Products Limited Reports NIL Interest Payment Obligations for Q1FY27 Under SEBI Compliance
Triochem Products Limited filed its quarterly compliance report under SEBI Regulation 57(4), confirming NIL interest payment obligations for Q1FY27 (April-June 2026). The company stated it has not issued any debt or non-convertible securities, resulting in zero payment obligations. The report was submitted to BSE Limited on March 19, 2026, by Company Secretary Ureca Deolekar.
 no imag found
23Feb 26
Triochem Products Limited Re-submits Q3FY26 Unaudited Standalone Financial Results After Correcting Typographical Error
Triochem Products Limited re-submitted its Q3FY26 unaudited standalone financial results after correcting a typographical error in the Limited Review Report following BSE's regulatory observation. The company reported a net loss of Rs. 13.18 lakhs for Q3FY26 compared to a profit of Rs. 8.83 lakhs in Q3FY25, with total income declining to Rs. 22.06 lakhs from Rs. 45.85 lakhs year-over-year. The Board approved asset sales worth over Rs. 1,100 lakhs in fair market value to support future business ventures.
 no imag found
14Feb 26
Multiple Indian Companies Release Q3 FY26 Financial Results Under Regulation 33
Multiple Indian companies including Tivoli Construction, Triochem Products, Arya Capital Management, Twenty Five South Realty, and Hindalco have released their Q3 FY26 financial results under Regulation 33 compliance. The unaudited standalone and consolidated results cover the quarter and nine months ended December 31, 2025, with Board approvals obtained in February 2026.
 no imag found
13Feb 26
Triochem Products Limited Files Statement of Deviation for Q3 FY26 Under SEBI Regulation 32
Triochem Products Limited submitted its Statement of Deviation or Variation in Public Issue for Q3 FY26 ended December 31, 2025, confirming no fund raising activities during the quarter. The Audit Committee and auditors both confirmed the non-applicability of deviation statements due to absence of any public issues, rights issues, or preferential issues. The filing was made in compliance with SEBI Regulation 32(1) and demonstrates the company's adherence to regulatory transparency requirements.
 no imag found
07Jan 26
Triochem Products Limited Reports Zero Financial Debt in Q3FY26 Regulatory Filing
Triochem Products Limited reported zero outstanding debt and no defaults in its Q3FY26 regulatory filing with BSE. The company disclosed nil amounts for bank loans, unlisted debt securities, and total financial indebtedness for the quarter ended December 31, 2025, demonstrating a debt-free financial position during the reporting period.
 no imag found
13Dec 25
Triochem Products Completes ₹11.81 Crore Asset Sale Approval via Postal Ballot
Triochem Products has successfully concluded its postal ballot process with unanimous shareholder approval for the ₹11.81 crore asset sale in Maharashtra. The transaction, approved with 14,000 votes in favor and zero against, involves property disposal at significant premium over written down value, providing crucial funds to address the company's recent operational losses and support future strategic initiatives in the chemicals and pharmaceuticals sector.
 no imag found
04Nov 25
Triochem Products Limited Seeks Shareholder Approval for Rs 11.81 Crore Asset Sale to Related Parties
Triochem Products Limited has announced plans to sell non-core assets valued at Rs 11.81 crore to related parties. The assets include residential flats, an industrial plot with factory buildings, and plant and machinery. The buyers are M/s G Amphray Laboratories and Mr. Rajesh Ramu Deora, who are related parties. The company is seeking shareholder approval through a postal ballot, with voting open from November 13 to December 12. The sale is based on independent valuations and complies with regulatory requirements. The company states that the sale will not adversely impact its operations.
 no imag found
24Oct 25
Triochem Products Board Approves Sale of Non-Core Assets Worth Rs 11.81 Crore
Triochem Products Limited has approved the sale of non-core assets valued at Rs 11.81 crore. The sale includes properties and plant & machinery to G Amphray Laboratories for Rs 8.06 crore and a residential flat to director Rajesh Ramu Deora for Rs 3.75 crore. These assets contributed 0% to the company's turnover last year. The sale, subject to shareholder approval, is expected to complete by January 31, 2026. Proceeds will be used for new business ventures and strategic initiatives. The company has also approved amendments to Related Party Transaction policies and a postal ballot process.
 no imag found
18Aug 25
Triochem Products Reports Widened Q1 Net Loss of Rs. 15.24 Crore
Triochem Products Limited reported a net loss of Rs. 15.24 crore for Q1, a 58.42% increase from the previous year's Q1 loss of Rs. 9.62 crore. Total income remained relatively stable at Rs. 22.10 crore, down 3.79% year-on-year. Despite the net loss, the company reported a total comprehensive income of Rs. 89.27 crore. The Q1 EPS was negative Rs. 1.25, an improvement from the previous quarter's negative Rs. 18.44. The Board approved these unaudited financial results on August 14, prepared in accordance with Indian Accounting Standards.
 no imag found
Triochem Products
17.40
0.0
(0.0%)
1 Year Returns:0.00%
Industry Peers
Sun Pharmaceutical
1,621.20
(-3.51%)
Divis Laboratories
6,381.00
(+0.04%)
Torrent Pharmaceuticals
4,119.90
(-0.66%)
Dr Reddys Laboratories
1,326.30
(-0.35%)
Cipla
1,300.20
(-0.44%)
Lupin
2,280.60
(-2.60%)
Mankind Pharma
2,280.30
(-0.55%)
Zydus Life Science
929.50
(-1.78%)
Aurobindo Pharma
1,419.80
(-1.09%)
Glenmark Pharmaceuticals
2,316.20
(-0.81%)